Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation

Lymphoma Clinical Trial

Official title:

Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00996359
• Other study ID #: 020901
• Secondary ID: P30CA072720CDR00
• Status: Terminated
• Phase: Phase 1
• First received: October 15, 2009
• Last updated: September 13, 2013
• Start date: October 2009
• Est. completion date: November 2011

Study information

• Verified date: September 2013
• Source: Rutgers, The State University of New Jersey
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Giving low-dose total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect).

PURPOSE: This phase I trial is studying the side effects of donor stem cell transplant after total-body irradiation and to see how well it works in treating patients with relapsed or refractory hematologic cancer or acute myeloid leukemia or acute lymphocytic leukemia in complete remission.

Description:

OBJECTIVES:

Primary

• To evaluate the toxicity of irradiated haploidentical allogeneic cellular therapy after low-dose total-body irradiation and no pharmacologic graft-vs-host disease prophylaxis in patients with relapsed or refractory hematologic malignancies or patients with acute myeloid leukemia (AML) or acute lymphoblastic leukemia in second or greater complete remission (CR2).

Secondary

• To evaluate immunologic parameters before and after haploidentical therapy.

• To demonstrate host anti-leukemia T-cells in a subset of patients with AML who are HLA-A2-positive.

• To observe any evidence of antitumor activity within the confines of this pilot study and/or assess the duration of remission in those patients who enter the study in CR2.

OUTLINE: Patients undergo low-dose total-body irradiation and infusion of irradiated donor cells on day 0. Patients also receive filgrastim subcutaneously (SC) daily or pegfilgrastim SC every 14 days starting on day 1.

Patients in complete remission (CR) or with persistent disease undergo irradiated donor lymphocyte infusion (DLI) at 8 weeks. Repeat irradiated DLI is administered if patients remain in CR or achieve stable or responding disease after the second infusion (if confirmed by histologic assessment) or third infusion (if confirmed by radiographic assessment). DLI repeats every 8 weeks pending disease and clinical status up to a total of 6 infusions over a 12-month period.

Blood samples are collected at baseline, upon recovery of counts, and then monthly thereafter for immunologic studies.

After completion of study treatment, patients are followed up periodically.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 4
• Est. completion date: November 2011
• Est. primary completion date: November 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 13 Years and older

Eligibility

DISEASE CHARACTERISTICS:

• Patients over 18 years old must meet the following criteria:

• Histologically confirmed hematologic malignancy and not a candidate for a standard allogeneic transplantation

• High-risk disease, including:

• Refractory/relapsed acute myeloid leukemia (AML) or AML in second or greater completion remission (CR2)

• Relapsed or refractory acute lymphoblastic leukemia (ALL) or ALL in CR2

• Tyrosine kinase inhibitor-resistant chronic myelogenous leukemia in chronic, accelerated, or blast crisis

• Fludarabine-resistant chronic lymphocytic leukemia

• High-risk myelodysplastic syndrome (MDS) (i.e., MDS with a score = 1.5 by the International Scoring System)

• Chronic myelomonocytic leukemia

• Relapsed diffuse large cell non-Hodgkin lymphoma (NHL) with measurable disease after (or not eligible for) high-dose chemotherapy/autologous hematopoietic stem cell (HSC) rescue or allogeneic hematopoietic stem cell transplantation (HSCT)

• Relapsed follicular NHL, mantle cell lymphoma, or low-grade histology NHL with measurable disease after (or not eligible for) high-dose chemotherapy/autologous HSC rescue or allogeneic HSCT

• Relapsed or refractory high-grade/aggressive NHL (Burkitt lymphoma, lymphoblastic lymphoma, T-cell lymphoma, NK-like lymphoma) with measurable disease after (or not eligible for) high-dose chemotherapy/autologous HSC rescue or allogeneic HSCT

• Hodgkin lymphoma with measurable disease after (or not eligible for) high-dose chemotherapy/autologous HSC rescue or allogeneic HSCT

• Relapsed or refractory multiple myeloma after (or not eligible for) high-dose chemotherapy/autologous HSC rescue and following salvage therapy with thalidomide, lenalidomide, bortezomib or other FDA-approved multiple myeloma salvage therapies

• Patients 13-17 years old must meet the following criteria:

• Histologically confirmed hematologic malignancy and not a candidate for a standard allogeneic transplantation

• High-risk disease, including:

• Refractory/relapsed AML or AML in CR2

• Relapsed or refractory ALL or ALL in CR2

• Relapsed diffuse large cell NHL with measurable disease after (or not eligible for) high-dose chemotherapy/autologous HSC rescue or allogeneic HSCT

• Relapsed follicular NHL, mantle cell lymphoma (or low-grade histology NHL) with measurable disease after (or not eligible for) high-dose chemotherapy/autologous HSC rescue or allogeneic HSCT

• Relapsed or refractory high-grade/aggressive NHL (Burkitt lymphoma, lymphoblastic lymphoma, T-cell lymphoma, NK-like lymphoma) with measurable disease after (or not eligible for) high-dose chemotherapy/autologous HSC rescue or allogeneic HSCT

• Hodgkin lymphoma with measurable disease after (or not eligible for) high-dose chemotherapy/autologous HSC rescue or allogeneic HSCT

• Eligible for haploidentical irradiated cellular therapy

• No known active brain metastases or malignant meningitis

• Available partially (= 3/6 class I antigen) HLA-matched (by serology) related donor NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.

PATIENT CHARACTERISTICS:

• ECOG performance status (PS) 0-2

• Karnofsky PS 60-100% (for patients > 16 years) or Lansky PS 60-100% (for patients = 16 years)

• Patients who are unable to walk because of paralysis but who are up in a wheelchair will be considered ambulatory for the purpose of assessing PS

• Patients = 18 years:

• Total bilirubin < 1.5 times upper limit of normal (ULN) (unless attributable to Gilbert disease)

• DLCO/alveolar volume > 50%

• Serum creatinine < 2.0 mg/dL

• Patients 13-17 years:

• Creatinine clearance or radioisotope GFR = 70 mL/min OR serum creatinine based on age/gender as follows:

• 13 to < 16 years: 1.5 mg/dL (male) or 1.4 mg/dL (female)

• = 16 years: 1.7 mg/dL (male) or 1.4 mg/dL (female)

• AST/ALT = 2.5 times ULN for age

• Total bilirubin < 2.0 mg/dL (unless attributable to Gilbert syndrome)

• Shortening fraction = 27% by ECHO or ejection fraction = 50% by radionuclide angiogram

• FEV_1, forced vital capacity, and DLCO corrected for hemoglobin = 60% by pulmonary function tests (PFTs)

• Children unable to cooperate for PFTs must meet the following criteria:

• No evidence of dyspnea at rest

• No exercise intolerance

• No requirement for supplemental oxygen therapy

• Any other organ dysfunction thought to be secondary to disease will be considered separately and the patient will be eligible at the physician's discretion

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception before, during, and for 24 weeks after study treatment

• No known HIV positivity

• No history of current or prior medical problems that, in the investigator's opinion, would prevent administration of study treatment or assessment of response due to excess toxicity

• No active uncontrolled infections or other medical, psychological, or social conditions that might increase the likelihood of patient adverse effects or poor outcomes

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• No corticosteroids within 2 weeks before receiving irradiated donor lymphocyte infusion

• No medications that might increase the likelihood of patient adverse effects or poor outcomes

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Leukemia
• Lymphoma
• Multiple Myeloma
• Multiple Myeloma and Plasma Cell Neoplasm
• Myelodysplastic Syndromes
• Neoplasms, Plasma Cell
• Plasmacytoma
• Preleukemia

Intervention

Biological:
• Irradiated haploidentical allogeneic lymphocytes
Partially HLA-matched irradiated donor lymphocytes will be infused after total body irradiation.

Radiation:
• total-body irradiation
100 cGy TBI

Locations

Country	Name	City	State
United States	Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School	New Brunswick	New Jersey

Sponsors (2)

Lead Sponsor	Collaborator
University of Medicine and Dentistry of New Jersey	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Toxicity		3 years	Yes
Secondary	Immunologic parameters before and after haploidentical therapy		3 years	No
Secondary	Anti-tumor activity and/or duration of remission in those patients who enter the study in second complete remission or greater		3 years	No
Secondary	Treatment-related mortality		3 years	Yes